Cytokinetics

Company snapshot

Cytokinetics, Incorporated, is a [biopharmaceutical](en.wikipedia.org/wiki/Biopharmaceutical) company based in [South San Francisco, California](en.wikipedia.org/wiki/South_San_Francisc), that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by impaired or declining muscle function. | Headquarters in South San Francisco | - | | --- | -

• 5 active pipeline program(s) linked via ClinicalTrials.gov.
• 5 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Cytokinetics. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Cytokinetics.

1. Jun 8, 2026 Clinical update

   CY 6033 — Phase 3

2. Jun 8, 2026 Clinical update

   CY 6023 — Phase 3

3. Jun 8, 2026 Clinical update

   CY 6032 — Phase 3

4. Jun 8, 2026 Clinical update

   CY 6022 — Phase 2

5. Jun 8, 2026 Clinical update

   CY 1033 — Phase 3

View all clinical trial activity →

• What is Cytokinetics?

  Cytokinetics (Ireland) is a pharma organization headquartered in GB. Primary therapeutic focus areas include Symptomatic hypertrophic cardiomyopathy (HCM), SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY, Heart Failure With Reduced Ejection Fraction, Symptomatic Obstructive H

• Is Cytokinetics publicly traded?

  Cytokinetics appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Cytokinetics develop or market?

  We link 7 drug profile(s) where Cytokinetics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/cytokinetics-ireland-limited#company-drugs.

• What are the latest developments for Cytokinetics?

  In the last 12 months our linked public records show 5 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Cytokinetics focus on?

  Cytokinetics focuses on Symptomatic hypertrophic cardiomyopathy (HCM), SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY, Heart Failure With Reduced Ejection Fraction based on our analysis of their pipeline programs and drug development activities.